Does BPC-157 actually work?

Your gym friend swears BPC-157 fixed his elbow. He is not lying to you. His elbow hurt, he injected a peptide he bought online, and now it does not hurt. He can also name a podcast host, a pro athlete and half his gym who say the same. What he cannot name is a published clinical trial, because in thirty years, through all the hype, nobody has produced one.

This July, that gap collided with politics. A federal advisory panel voted to make BPC-157 and five other peptides easier to obtain legally, over the objections of the FDA's own scientists, who had gone looking for the human evidence and found almost none. The story of how that happened tells you most of what you need to know about the peptide boom.

What is BPC-157?

BPC-157 is a chain of fifteen amino acids copied from a fragment of a protective protein in human gastric juice. It was first described in the early 1990s by a research group in Zagreb, Croatia, which has driven most of the work on it since, a concentration of authorship that reviewers keep flagging. In animals, the results read like science fiction: faster tendon healing in rats, repaired ligaments, protected guts, regrown blood supply. That rat literature is real, it is extensive, and it is the entire engine of the hype. Gym culture even has a name for BPC-157 stacked with another unapproved peptide, TB-500: the wolverine stack, after the superhero who heals from anything.

The human evidence, counted

Rats are not small humans, so what happens when you count the human studies? A 2025 systematic review from the Hospital for Special Surgery found exactly one: a retrospective look at twelve knee-pain patients, seven of whom reported feeling better, with no control group. The only randomized trial in the record was presented as a conference abstract in 2005, involved delivering the peptide by enema, and was never published in full. When FDA reviewers totalled every identified human exposure ahead of this year's hearings, they arrived at roughly 81 people, dosed for two weeks or less, with immunogenicity never assessed.

That is the state of play after three decades: extraordinary claims, a rodent mountain, and a human molehill. As the FDA's compounding-risk assessment put it, the agency lacks sufficient information to know whether the drug would cause harm in people.

So why is it about to get easier to buy?

Not because new evidence arrived. In 2023, the FDA classified BPC-157 among peptides posing significant safety risk for pharmacy compounding. Then the politics shifted. In February 2026, per reporting cited by Health Affairs, the health secretary told a podcast audience the FDA would make around fourteen peptides more accessible and called the earlier restriction illegal. In July, the FDA's Pharmacy Compounding Advisory Committee took up seven peptides and voted six of them forward, BPC-157 among them by 8 votes to 6, in each case against the written assessment of FDA scientific staff. The votes are advisory, and formal rulemaking still has to happen, but the direction is unmistakable.

The votes and the conflicts

Who voted matters. Investigations by STAT and The Washington Post found at least seven members of the newly constituted panel had ties to peptide sellers, clinics or related businesses, and Health Affairs' analysis of the meeting record notes that every winning vote came from those eight members, with no conflict-of-interest waivers posted as federal law requires. Stem-cell scientist Paul Knoepfler's assessment was simple: many members who voted in favor stood to gain. Cardiologist Eric Topol was blunter about the science itself.

Meanwhile, the market is not waiting

While the rulemaking grinds, the sales floor is expanding. Bodybuilding.com launched its own peptide line this September. A startup called System raised 20 million dollars for a vertically integrated peptide platform. Analysts quoted by The Guardian estimate telehealth peptide prescribing at up to 2.2 billion dollars a year, and one physician interviewed by the LA Times put the gray market at 7 to 10 billion, an estimate, but a telling one. The product is moving from bodybuilder forums to your pharmacy app faster than the evidence is moving anywhere.

What is actually in the vial

For the majority buying from research chemical sites, there is a prior question: is it even BPC-157? When WIRED commissioned lab tests of gray-market vials this year, the BPC-157 sample contained none of the peptide at all. A researcher's preliminary testing cited by Medscape estimates 40 to 75 percent of gray-market peptides fail basic quality standards, a figure from a preprint, so treat it as provisional, but it rhymes with everything else found in unregulated injectables, including endotoxin contamination in every gray-market semaglutide vial one peer-reviewed study tested. "Research use only" is a legal disclaimer, not a purity standard.

The risks nobody has measured

The honest answer on safety is that nobody knows, and the way nobody knows is specific. The same blood-vessel growth that makes BPC-157 interesting for healing is a mechanism that oncologists watch warily, since tumors also want blood supply; the FDA's 2023 action cited that concern, and with roughly 81 short-term human exposures on record, no one has looked properly. There is one group with a concrete, measurable risk today: tested athletes. BPC-157 has been on WADA's prohibited list since 2022, at all times, in and out of competition. Your gym friend's elbow protocol is a career-ending violation for a competitor.

The bottom line

BPC-157 might work. It is entirely possible that inside that rat literature is a genuinely useful human medicine, and the way to find out has been available for thirty years: run a real trial. Until someone does, what is being sold is a story, at gray-market purity, with tumor-adjacent biology and a regulator being pushed to open the gates by a panel that reporters found was seeded with sellers. If your tendon hurts, the boring evidence still points to load management and physiotherapy. If the compounding rule changes, that will change what you can legally buy. It will not change what anyone knows.

What we still do not know, said plainly: whether BPC-157 works in humans, at what dose, and at what risk. A proper trial could change every paragraph above, and if one appears, this article will change with it, logged in the updates section below.